GlassScriptPhysician profile
Jan M Rothman
NPI 1639176027
$6,076.09
in general payments reported to CMS, 2019-2025
30 companies · $253 in 2025
The $253 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,050 · 2021: $1,350 · 2022: $522 · 2023: $2,558 · 2024: $343 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,220 · Food and Beverage: $709 · Education: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,220.00 |
| Food and Beverage | $709.06 |
| Education | $224.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,636.33 | 2019-2023 | Calquence, Lynparza, Imfinzi |
| Jazz Pharmaceuticals INC. | $1,387.94 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $402.87 | 2021-2024 | Augtyro, Opdivo |
| Incyte Corporation | $198.95 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $198.55 | 2019-2025 | Welireg |
| Pfizer INC. | $160.31 | 2019 | |
| Amgen INC. | $124.99 | 2025 | Imdelltra (Amg757) |
| Janssen Biotech, INC. | $116.45 | 2019-2025 | Rybrevant, Carvykti |
| Takeda Pharmaceuticals U.S.A., INC. | $113.61 | 2019 | |
| Stryker Corporation | $112.79 | 2023 | Spinejack |
| Novartis Pharmaceuticals Corporation | $90.70 | 2019 | |
| Eisai INC. | $82.41 | 2019-2022 | |
| Lilly USA, LLC | $59.19 | 2019 | |
| Genentech USA, INC. | $58.36 | 2019 | |
| Genentech, INC. | $49.95 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.82 | 2019 | |
| Celgene Corporation | $31.50 | 2022 | |
| Seagen INC. | $24.59 | 2019 | |
| Gilead Sciences, INC. | $23.61 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $22.33 | 2019 | |
| Abbvie INC. | $20.93 | 2019 | |
| Clovis Oncology, INC. | $20.71 | 2019 | |
| Life Molecular Imaging LTD | $16.50 | 2024 | Neuraceq |
| Astellas Pharma US INC | $14.68 | 2019 | |
| Tesaro, INC. | $14.40 | 2019 | |
| Verastem, INC. | $14.18 | 2019 | |
| Alexion Pharmaceuticals, INC. | $12.26 | 2019 | |
| Acrotech Biopharma INC. | $11.97 | 2021 | |
| Amag Pharmaceuticals, INC. | $11.86 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jan Rothman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.